Bevacizumab (Avastin®), the only approved monoclonal antibody for anti‐angiogenic therapy in first‐line treatment of eligible advanced lung cancer patients [30], targets VEGF‐A and sterically disrupts VEGF binding to its receptor expressed on ECs, thereby abolishing VEGF’s angiogenic activity [31]. This evidence concerns the gene VEGFA and lung cancer.